Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Forimtamig by F. Hoffmann-La Roche for Refractory Multiple Myeloma: Likelihood of Approval
Forimtamig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Refractory Multiple Myeloma. According to...
Data Insights
Forimtamig by F. Hoffmann-La Roche for Relapsed Multiple Myeloma: Likelihood of Approval
Forimtamig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Relapsed Multiple Myeloma. According to...